A Novel Conditionally Replicative Adenovirus Vector Targeting Telomerase-Positive Tumor Cells

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1439-1445

  Huang, Qian ^a,b   Zhang, Xiuwu ^a   Wang, He ^a,c   Yan, Bin ^a   Kirkpatrick, John ^a   Dewhrist, Mark W ^a   Li, Chuan Yuan ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ONCOLYTIC VIRUS; TELOMERASE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; E1A GENE; EPITHELIUM CELL; FIBROBLAST; FLUORESCENCE MICROSCOPY; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; VIRUS GENE; VIRUS PLAQUE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; CELL LINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; GENETIC VECTORS; HUMANS; LUMINESCENT PROTEINS; MALE; PROMOTER REGIONS (GENETICS); PROSTATE; PROSTATIC NEOPLASMS; TELOMERASE; TIME FACTORS;

EID: 1642395711     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0122     Document Type: Article

References (31)

1. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
2. Kirn, D. H., and McCormick, F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today, 2: 519-527, 1996.
3. Alemany, R., Balague, C., and Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727, 2000.
4. Kirn, D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene, 19: 6660-6669, 2000.
5. DeWeese, T. L., van der Poel, H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G., and Simons, J. W. A Phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res., 61: 7464-7472, 2001.
6. Li, J. H., Chia, M., Shi, W., Ngo, D., Strathdee, C. A., Huang, D., Klamut, H., and Liu, F. F. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res., 62: 171-178, 2002.
7. Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M. S., Hsieh, C. L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., and Chung, L. W. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res., 61: 6012-6019, 2001.
8. Harrington, L., McPhail, T., Mar, V., Zhou, W., Oulton, R., Bass, M. B., Arruda, I., and Robinson, M. O. A mammalian telomerase-associated protein. Science (Wash. DC), 275: 973-977, 1997.
9. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L., Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A., and Weinberg, R. A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90: 785-795, 1997.
10. Kolquist, K. A., Ellisen, L. W., Counter, C. M., Meyerson, M., Tan, L. K., Weinberg, R. A., Haber, D. A., and Gerald, W. L. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat. Genet., 19: 182-186, 1998.
11. Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L., Coviello, G. M., Wright, W. E., Weinrich, S. L., and Shay, J. W. Specific association of human telomerase activity with immortal cells and cancer. Science (Wash. DC), 266: 2011-2015, 1994.
12. Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M., and Inoue, M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res., 59: 551-557, 1999.
13. Majumdar, A. S., Hughes, D. E., Lichtsteiner, S. P., Wang, Z., Lebkowski, J. S., and Vasserot, A. P. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther., 8: 568-578, 2001.
14. Bett, A. J., Haddara, W., Prevec, L., and Graham, F. L. An effcient and flexible system for construction of adenovirus vectors with insertion or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. USA, 91: 8802-8806, 1994.
15. He, T. C., Zhou, S., da Costa, L. T., Yu, J., Kinzler, K. W., and Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA, 95: 2509-2514, 1998.
16. Graham, F. L., and Prevec, L. Methods for construction of adenovirus vectors. Mol. Biotechnol., 3: 207-220, 1995.
17. Garn, H., Krause, H., Enzmann, V., and Drossler, K. An improved MTT assay using the electron-coupling agent menadione. J. Immunol. Methods, 168: 253-256, 1994.
18. Ries, S., and Korn, W. M. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br. J. Cancer, 86: 5-11, 2002.
19. Oncologist Magazine. Onyx plans Phase III trial of ONYX-015 for head and neck cancer. Oncologist, 4: 432, 1999.
20. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
21. Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res., 57: 2559-2563, 1997.
22. Yu, D. C., Chen, Y., Dilley, J., Li, Y., Embry, M., Zhang, H., Nguyen, N., Amin, P., Oh, J., and Henderson, D. R. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res., 61: 517-525, 2001.
23. Yu, D. C., Chen, Y., Seng, M., Dilley, J., and Henderson, D. R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res., 59: 4200-4203, 1999.
24. Kurihara, T., Brough, D. E., Kovesdi, I., and Kufe, D. W. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J. Clin. Investig., 106: 763-771, 2000.
25. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., and Wold, W. S. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol., 75: 3314-3324, 2001.
26. Adachi, Y., Reynolds, P. N., Yamamoto, M., Wang, M., Takayama, K., Matsubara, S., Muramatsu, T., and Curiel, D. T. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res., 61: 7882-7888, 2001.
27. Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., McCormick, F., and Fattaey, A. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell, 1: 325-337, 2002.
28. Poremba, C., Hero, B., Goertz, H. G., Scheel, C., Wai, D., Schaefer, K. L., Christiansen, H., Berthold, F., Juergens, H., Boecker, W., and Dockhorn-Dworniczak, B. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly. Klin. Padiatr., 213: 186-190, 2001.
29. Streutker, C. J., Thorner, P., Fabricius, N., Weitzman, S., and Zielenska, M. Telomerase activity as a prognostic factor in neuroblastomas. Pediatr. Dev. Pathol., 4: 62-67, 2001.
30. Greenberg, R. A., O'Hagan, R. C., Deng, H., Xiao, Q., Hann, S. R., Adams, R. R., Lichtsteiner, S., Chin, L., Morin, G. B., and DePinho, R. A. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene, 18: 1219-1226, 1999.
31. Wu, K. J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., and Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. Nat. Genet., 21: 220-224, 1999.